Calcium homeostasis and skeletal integrity in individuals with familial hypercholesterolemia and aortic calcification

Zuhier Awan, Khalid Alwaili, Ali AlShahrani, Lisa Langsetmo, David Goltzman, Jacques Genest

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

BACKGROUND: Familial hypercholesterolemia (FH) due to mutations in the low-density lipoprotein receptor (LDLR) gene exhibit severe, premature aortic calcification in a gene-dosage, age-dependent fashion. We sought to determine potential associations with mineral and skeletal indices. METHODS: We obtained computed tomography (CT) scan aortic calcium scores (AoCSs) in 19 (age 49 [SD 14] years) FH patients heterozygous for the 15-kb deletion at the LDLR gene and examined associations with various indices of mineral and skeletal homeostasis. RESULTS: We found that mean bone mineral density (BMD) at the femoral neck in these patients did not differ from age-, sex-, and province-matched mean BMD, and we observed no association of AoCS with any marker of bone resorption. However, there were negative correlations between AoCS and serum concentrations of osteocalcin, a marker of bone formation (r = -0.64, P = 0.0034), urinary calcium (r = -0.59, P = 0.0085), and estimated glomerular filtration rate (r = -0.67, P = 0.0019). CONCLUSIONS: We found that LDLR-deficient FH was not associated with obvious bone loss or a major disturbance in calcium homeostasis. The lack of LDLR, however, may modify osteoblast function or extracellular calcium distribution, manifesting as lower bone formation, and reduced calcium excretion, resulting in increased deposition in calcifying vascular tissue.

Original languageEnglish
Pages (from-to)1599-1607
Number of pages9
JournalClinical Chemistry
Volume56
Issue number10
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Hyperlipoproteinemia Type II
Homeostasis
Bone
Calcium
LDL Receptors
Minerals
Genes
Osteogenesis
Bone Density
Gene Dosage
Femur Neck
Osteocalcin
Osteoblasts
Bone Resorption
Glomerular Filtration Rate
Tomography
Blood Vessels
Tissue
Bone and Bones
Mutation

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Calcium homeostasis and skeletal integrity in individuals with familial hypercholesterolemia and aortic calcification. / Awan, Zuhier; Alwaili, Khalid; AlShahrani, Ali; Langsetmo, Lisa; Goltzman, David; Genest, Jacques.

In: Clinical Chemistry, Vol. 56, No. 10, 10.2010, p. 1599-1607.

Research output: Contribution to journalArticle

Awan, Zuhier ; Alwaili, Khalid ; AlShahrani, Ali ; Langsetmo, Lisa ; Goltzman, David ; Genest, Jacques. / Calcium homeostasis and skeletal integrity in individuals with familial hypercholesterolemia and aortic calcification. In: Clinical Chemistry. 2010 ; Vol. 56, No. 10. pp. 1599-1607.
@article{ed25be7708e9497fb68842097ebfd7bd,
title = "Calcium homeostasis and skeletal integrity in individuals with familial hypercholesterolemia and aortic calcification",
abstract = "BACKGROUND: Familial hypercholesterolemia (FH) due to mutations in the low-density lipoprotein receptor (LDLR) gene exhibit severe, premature aortic calcification in a gene-dosage, age-dependent fashion. We sought to determine potential associations with mineral and skeletal indices. METHODS: We obtained computed tomography (CT) scan aortic calcium scores (AoCSs) in 19 (age 49 [SD 14] years) FH patients heterozygous for the 15-kb deletion at the LDLR gene and examined associations with various indices of mineral and skeletal homeostasis. RESULTS: We found that mean bone mineral density (BMD) at the femoral neck in these patients did not differ from age-, sex-, and province-matched mean BMD, and we observed no association of AoCS with any marker of bone resorption. However, there were negative correlations between AoCS and serum concentrations of osteocalcin, a marker of bone formation (r = -0.64, P = 0.0034), urinary calcium (r = -0.59, P = 0.0085), and estimated glomerular filtration rate (r = -0.67, P = 0.0019). CONCLUSIONS: We found that LDLR-deficient FH was not associated with obvious bone loss or a major disturbance in calcium homeostasis. The lack of LDLR, however, may modify osteoblast function or extracellular calcium distribution, manifesting as lower bone formation, and reduced calcium excretion, resulting in increased deposition in calcifying vascular tissue.",
author = "Zuhier Awan and Khalid Alwaili and Ali AlShahrani and Lisa Langsetmo and David Goltzman and Jacques Genest",
year = "2010",
month = "10",
doi = "10.1373/clinchem.2010.147066",
language = "English",
volume = "56",
pages = "1599--1607",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "10",

}

TY - JOUR

T1 - Calcium homeostasis and skeletal integrity in individuals with familial hypercholesterolemia and aortic calcification

AU - Awan, Zuhier

AU - Alwaili, Khalid

AU - AlShahrani, Ali

AU - Langsetmo, Lisa

AU - Goltzman, David

AU - Genest, Jacques

PY - 2010/10

Y1 - 2010/10

N2 - BACKGROUND: Familial hypercholesterolemia (FH) due to mutations in the low-density lipoprotein receptor (LDLR) gene exhibit severe, premature aortic calcification in a gene-dosage, age-dependent fashion. We sought to determine potential associations with mineral and skeletal indices. METHODS: We obtained computed tomography (CT) scan aortic calcium scores (AoCSs) in 19 (age 49 [SD 14] years) FH patients heterozygous for the 15-kb deletion at the LDLR gene and examined associations with various indices of mineral and skeletal homeostasis. RESULTS: We found that mean bone mineral density (BMD) at the femoral neck in these patients did not differ from age-, sex-, and province-matched mean BMD, and we observed no association of AoCS with any marker of bone resorption. However, there were negative correlations between AoCS and serum concentrations of osteocalcin, a marker of bone formation (r = -0.64, P = 0.0034), urinary calcium (r = -0.59, P = 0.0085), and estimated glomerular filtration rate (r = -0.67, P = 0.0019). CONCLUSIONS: We found that LDLR-deficient FH was not associated with obvious bone loss or a major disturbance in calcium homeostasis. The lack of LDLR, however, may modify osteoblast function or extracellular calcium distribution, manifesting as lower bone formation, and reduced calcium excretion, resulting in increased deposition in calcifying vascular tissue.

AB - BACKGROUND: Familial hypercholesterolemia (FH) due to mutations in the low-density lipoprotein receptor (LDLR) gene exhibit severe, premature aortic calcification in a gene-dosage, age-dependent fashion. We sought to determine potential associations with mineral and skeletal indices. METHODS: We obtained computed tomography (CT) scan aortic calcium scores (AoCSs) in 19 (age 49 [SD 14] years) FH patients heterozygous for the 15-kb deletion at the LDLR gene and examined associations with various indices of mineral and skeletal homeostasis. RESULTS: We found that mean bone mineral density (BMD) at the femoral neck in these patients did not differ from age-, sex-, and province-matched mean BMD, and we observed no association of AoCS with any marker of bone resorption. However, there were negative correlations between AoCS and serum concentrations of osteocalcin, a marker of bone formation (r = -0.64, P = 0.0034), urinary calcium (r = -0.59, P = 0.0085), and estimated glomerular filtration rate (r = -0.67, P = 0.0019). CONCLUSIONS: We found that LDLR-deficient FH was not associated with obvious bone loss or a major disturbance in calcium homeostasis. The lack of LDLR, however, may modify osteoblast function or extracellular calcium distribution, manifesting as lower bone formation, and reduced calcium excretion, resulting in increased deposition in calcifying vascular tissue.

UR - http://www.scopus.com/inward/record.url?scp=77957734152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957734152&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2010.147066

DO - 10.1373/clinchem.2010.147066

M3 - Article

VL - 56

SP - 1599

EP - 1607

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 10

ER -